Source: Lieyun Network
According to Arterial Network, Yellwin, a Beijing-based company focused on the research and development of innovative medical devices for cardiac surgery, announced the completion of a multi-million-yuan A++ round of financing, exclusively invested by the Beijing Medical and Health Industry Investment Fund.
This round of financing will be mainly used in two directions: one is to further the research and development of innovative devices for the entire process of coronary heart disease diagnosis and treatment, as well as new products like the pulsatile left ventricular assist system; the other is to accelerate the market promotion of already approved products such as cardiac stabilizers. Empowered by this round of financing, Yellwin will comprehensively strengthen its R&D innovation and market penetration capabilities in the cardiovascular field, continuously consolidating its leading position in technology.
Tianyancha shows that the company was established in 2021 as a research and development enterprise for cardiac surgical implantable medical devices, initiated by a team of cardiac surgery experts with over 20 years of clinical experience from Beijing Anzhen Hospital, Capital Medical University.
The company focuses on the innovative product development and transformation of full-process medical devices and equipment solutions for cardiac surgery. Its series of products include a number of pioneering exclusive results in China, such as coronary artery bypass heart stabilizers, intraoperative ultrasound flow detectors, left ventricular assist devices, and coronary anastomosis assistance systems.
Based on the founding team's many years of clinical experience in cardiac surgery, Yellwin has tapped into clinical needs and developed multiple medical devices by integrating the current state of related fields. These include a new generation of heart stabilizers, vascular anastomosis quality control systems, and coronary heart disease scoring systems, all of which are either China’s first or fill a market gap.
Previously, the company completed a total of three rounds of financing in 2021 and 2023, with investors including IDG Capital, Zhongnan Venture Capital, Hotang Venture Capital, and others.